排序方式: 共有87条查询结果,搜索用时 63 毫秒
1.
2.
精子线粒体DNA损伤与男性不育 总被引:1,自引:0,他引:1
精子线粒体DNA与男性生育能力密切相关,由于它缺少组蛋白和DNA结合蛋白的保护,易受活性氧的攻击,造成损伤,增加突变率,这被认为是引起男性不育的重要原因。精子mtDNA突变和数量的检测是评价男性生育力的重要方法。对精子mtDNA损伤的研究有重要意义。 相似文献
3.
目的:考察反复给予雷诺嗪{N-(2,6二甲基苯基)-2-4-[2-羟基-3-(2-甲氧苯氧基)丙基]-1-哌嗪乙酰胺}对大鼠产生的毒性反应。方法:SD大鼠随机分为雷诺嗪高、中、低剂量(400,150和50 mg.kg-1.d-1)组和溶媒对照(0.5%羧甲基纤维素钠)组,每组32只大鼠,雌雄各半。各组均灌胃给予等体积的药物或溶媒(20 mL.kg-1),每周给药7 d,连续给药4周。停药后每组留12只动物(雌雄各半)再饲喂2周进行恢复性观察。观察动物一般状况、体重、进食量、饮水量、血液学、血液生化学、脏器重量系数及组织病理学改变。结果:雷诺嗪400 mg.kg-1组大鼠给药初期出现活动减少、呆滞和抽搐,体重增加值低于对照组,饮水量、丙氨酸氨基转换酶(ALT)、尿素氮(BUN)、总胆固醇(T-Cho)及肝、肾系数高于对照组。雷诺嗪50和150 mg.kg-1组各项指标与对照组比较均无统计学差异。恢复期各剂量的各项指标与对照组比较均无统计学差异。结论:雷诺嗪150 mg.kg-1为安全剂量,400 mg.kg-1有短时神经系统毒性并对动物生长,肝、肾功能和脂代谢产生可逆性影响。 相似文献
4.
慢性睾丸痛之辨证治疗 总被引:1,自引:0,他引:1
1病因病机慢性睾丸痛属中医学“子痛”、“子痈”范畴,早在《内经》就对其作了描述,《素问·缪刺论》曰:“邪客于足厥阴之络,令人卒疝暴痛。”元·张子和在《儒门事亲·疝本肝经且通勿塞状》中曰:“两丸寒痛,足阳明脉气之所发也。”“邪气客于中厥阴之经,令人卒疝,故病阴丸痛也。”明代虞抟在《医学正传·疝气》中指出:“子和论七疝,病源至为详悉,但其处方一以攻下法为主治,不能使人无疑耳!……我丹溪先生独断为湿热,此发为古人之所未发也。夫热郁于中而寒束于外,宜其非常之痛,故治法宜驱逐本经之湿热,消导下焦之瘀血。”现代医家多认为本病… 相似文献
5.
在占生育人口15%的不育夫妇中,男性不育因素约占33.15%.而少精症、弱精症以及少弱精症约占男性不育的46%。现代医学对此殊无良策,祖国传统医学在长期的临床摸索过程中积累了一定的治疗经验,并取得一定的临床疗效。 相似文献
6.
7.
Objective: To evaluate the efficacy and safety of Shugan Yiyang Capsule (SGYY, 疏肝益阳ficiency Syndrome type with or without blood stasis. Methods: A multi-centered, randomized, double-blinded, placebo-controlled trial in 304 patients was conducted by dividing them into 3 groups, who received re101), 1.0g taken three times a day for 4 weeks. Besides, 205 patients were arranged in an open-label studyand treated with SGYY 1.0 g taken three times a day for 4 weeks. The total effective rate, total remarkablyeffective rate, erection recovery rate tested by penis hardness test ring, time taken for improving erection among groups, as well as therapeutic effect between psychogenic ED group and mild arteriogenic ED group were compared. Adverse reactions related to SGYY were recorded. And a 3-month follow-up study was conducted on 105 cured patients. Results: The trial was completed in 500 patients. The total effective rate and total remarkably effective rate in the SGYY treated double-blinded group were 88.0% and 64.0% respectively, and those in the open-label group 90.5% and 65.0%, respectively, all significantly higher th an thosein the placebo (21.0%, 6.0%) and SYBS groups (60.0%, 29.0%), P<0.01. At the same time, the e rection recovery rate and improving time in SGYY group were significantly better than those in other groups ( P<0.01). No adverse reactions related to SGYY were found. The successful rate of potency to have intercourse within 3 months was over 80% (100 patients out of the 105 cured patients). Conclusion: SGYY was an effective and safe treatment for patients with psychogenic and mild arteriogenic ED of Gan stagnation and Shen deficiency Syndrome type with or without blood stasis, especially for psychogenic ED patients. 相似文献
8.
9.
10.